Haematologic malignancies
Celgene Corp. funds extensive research in acute myeloid leukemia, myelodysplastic syndromes, and myeloid malignancies, with additional activity in myeloproliferative neoplasms and myelofibrosis. Its trial portfolio also includes studies in multiple myeloma and other plasma cell disorders, reflecting a major focus on refractory and relapsed blood cancers.
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Multiple myeloma
- Myelofibrosis
- Myeloid malignancies
Research in this area also extends to anemia linked with marrow failure and clonal blood disorders.
B-cell lymphomas and related cancers
The sponsor supports studies across non-Hodgkin lymphoma subtypes, including follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, and primary central nervous system lymphoma. Its oncology portfolio also includes work in high-risk large B-cell lymphoma and other aggressive B-cell lymphomas.
- Follicular lymphoma
- Diffuse large B-cell lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Non-Hodgkin lymphoma
Several studies address relapsed and refractory lymphoma settings, including advanced and newly diagnosed disease.
Plasma cell and transfusion-dependent disorders
A major therapeutic interest is multiple myeloma, including newly diagnosed, relapsed and refractory, and post-transplant settings. Celgene Corp. also funds research in beta-thalassemia, alpha-thalassemia, and transfusion-dependent anemia, with attention to disorders where ineffective erythropoiesis drives chronic blood loss or transfusion need.
- Multiple myeloma
- Beta-thalassemia
- Alpha-thalassemia
- Transfusion-dependent anemia
- Erythroid disorders
Its studies include pediatric and adult populations across inherited and acquired haematologic disease.
Autoimmune and inflammatory diseases
The sponsor has active clinical research in systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, systemic sclerosis, and idiopathic inflammatory myopathy. It also funds studies in myasthenia gravis and other immune-mediated conditions affecting multiple organ systems.
- Systemic lupus erythematosus
- Lupus nephritis
- Rheumatoid arthritis
- Systemic sclerosis
- Myasthenia gravis
This portfolio includes both systemic autoimmune disease and organ-specific immune complications.
Neurology, solid tumors, and advanced malignancies
Celgene Corp. also supports research in multiple sclerosis, including relapsing and progressive forms, as well as spasticity associated with neurologic disease. In oncology, its studies extend to metastatic castration-resistant prostate cancer, non-small cell lung cancer, small cell lung cancer, glioblastoma, basal cell carcinoma, and other advanced solid tumors.
- Multiple sclerosis
- Metastatic castration-resistant prostate cancer
- Non-small cell lung cancer
- Glioblastoma
- Advanced solid tumors
These trials cover both neurologic symptom management and treatment of later-stage cancer.
